BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Penn Engineering Events - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Penn Engineering Events
X-ORIGINAL-URL:https://seasevents.nmsdev7.com
X-WR-CALDESC:Events for Penn Engineering Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220329T153000
DTEND;TZID=America/New_York:20220329T170000
DTSTAMP:20260406T012712
CREATED:20220131T154059Z
LAST-MODIFIED:20220131T154059Z
UID:6225-1648567800-1648573200@seasevents.nmsdev7.com
SUMMARY:Herman P. Schwan Distinguished Lecture: "Nucleoside-modified mRNA-LNP therapeutics" (Drew Weissman\, Perelman School of Medicine)
DESCRIPTION:Vaccines prevent 4-5 million deaths a year making them the principal tool of medical intervention worldwide. Nucleoside-modified mRNA was developed over 15 years ago and has become the darling of the COVID-19 pandemic with the first 2 FDA approved vaccines based on it. These vaccines show greater than 90% efficacy and outstanding safety in clinical use. The mechanism for the outstanding immune response induction are the prolonged production of antigen leading to continuous loading of germinal centers and the adjuvant effect of the LNPs\, which selectively stimulate T follicular helper cells that drive germinal center responses. Vaccine against many pathogens\, including HIV\, HCV\, HSV2\, CMV\, universal influenza\, coronavirus variants\, pancoronavirus\, nipah\, norovirus\, malaria\, TB\, and many others are currently in development. Nucleoside-modified mRNA is also being developed for therapeutic protein delivery. Clinical trials with mRNA encoded monoclonal antibodies are underway and many other therapeutic or genetic deficient proteins are being developed. Finally\, nucleoside-modified mRNA-LNPs are being developed and used for gene therapy. Cas9 knockout to treat transthyretin amyloidosis has shown success in phase 1 trials. We have developed the ability to target specific cells and organs\, including lung\, brain\, heart\, CD4+ cells\, all T cells\, and bone marrow stem cells\, with LNPs allowing specific delivery of gene editing and insertion systems to treat diseases such as sickle cell anemia\, Nucleoside-modified mRNA will have an enormous potential in the development of new medical therapies. \nThe Herman P. Schwan Distinguished Lecture is in honor of one of the founding members of the Department of Bioengineering\, who emigrated from Germany after World War II and helped create the field of bioengineering in the US. It recognizes people with a similar transformative impact on the field of bioengineering. \nThis lecture will be held live in person (Bodek Lounge\, Houston Hall) and via Zoom. A reception will follow the in-person event.\nZoom link\nPassword: schwan22
URL:https://seasevents.nmsdev7.com/event/herman-p-schwan-distinguished-lecture-drew-weissman/
LOCATION:Bodek Lounge\, Houston Hall\, 3417 Spruce St\, Philadelphia\, PA\, 19104\, United States
CATEGORIES:Seminar,Distinguished Lecture,Faculty
ORGANIZER;CN="Bioengineering":MAILTO:be@seas.upenn.edu
END:VEVENT
END:VCALENDAR